Lucem Health announced the availability of a new early disease detection solution, Lucem Health Reveal, which leverages existing EHR data to identify those at higher risk of serious or chronic disease.
Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.
Addressing Chronic & serious Diseases
Roughly 60% of Americans live with at least one serious or chronic disease, such as cancer, diabetes, stroke, or heart disease. Early diagnosis and personalized intervention can improve outcomes and quality of life for patients, enabling treatment before a condition may become more difficult and expensive to manage.
Part of the Mayo Clinic Platform portfolio, Lucem Health says it is committed to bringing proactive AI insights that may reduce delays in diagnosis and treatment, genuinely impacting patient lives and improving the clinician experience.
“The future of healthcare is proactive, not reactive, and clinical AI has the potential to transform our industry by reducing dangerous and costly delays in diagnosis and treatment,” says Ori Geva, co-founder and CEO of EarlySign. “We’re thrilled that our work with Lucem Health on the Reveal solutions will further demonstrate how clinicians, researchers, and care providers can use AI pragmatically to genuinely impact patient lives and the human experience of care.”
Lucem’s Reveal Solutions
Reveal solutions leverage the promise of AI for early disease detection, and respect clinicians’ limited capacity for added clicks, new workload, or administrative burden. Unlike many AI solutions that target the care team, Reveal focuses on boosting upstream patient identification and care coordination, thus prioritizing care without changing existing workflows.
The Lucem Health Reveal solutions developed in partnership with Medial EarlySign use clinical data already in patient charts to identify patients who appear to be at a higher risk for Diabetes or Lower GI disorders.
- Reveal for lower GI disorders: Identifies patients who appear to be at higher risk for colorectal cancer and other serious lower GI disorders.
- Reveal for diabetes: Identifies patients who appear to be at higher risk of undiagnosed diabetes.
- Reveal for prediabetes progression: Identifies patients who appear to be at higher risk of progressing from prediabetes to diabetes within 12 months.
“Clinical AI helps providers identify patient risks that are hiding in plain sight – in the often-untapped patient data that exists at every clinic and health system in the United States,” says Sean Cassidy, founding CEO of Lucem Health. “The challenge is integrating these powerful tools into existing clinical workflows. Reveal solutions support current processes and work in tandem with population health management tools. The impact is far-reaching, prolonging patient lives and easing provider burden, while sidestepping common implementation headaches. We’re excited that the Medial EarlySign team is as committed as we are to reimagining how we detect and treat diseases.”